Clinical Significance of 1-year Treatment with Raloxifene on Bone and Lipid Metabolism in Japanese Postmenopausal Women with Osteoporosis

• MAJIMA Takafumi

  Division of Metabolic Research, Clinical Research Institute, Center for Endocrine and Metabolic Diseases, National Hospital Organization, Kyoto Medical Center Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine Department of General Medicine, Rakuwakai Otowa Hospital

• KOMATSU Yasato

  Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine

• SHIMATSU Akira

  Division of Metabolic Research, Clinical Research Institute, Center for Endocrine and Metabolic Diseases, National Hospital Organization, Kyoto Medical Center

• SATOH Noriko

  Division of Metabolic Research, Clinical Research Institute, Center for Endocrine and Metabolic Diseases, National Hospital Organization, Kyoto Medical Center

• FUKAO Atsushi

  Department of Psychosomatic Medicine, Rakuwakai Otowa Hospital

• NINOMIYA Kiyoshi

  Department of General Medicine, Rakuwakai Otowa Hospital

• MATSUMURA Tadashi

  Department of General Medicine, Rakuwakai Otowa Hospital

• NAKAO Kazuwa

  Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine

Abstract

It has been well established that raloxifene (RLX) has beneficial effects on bone primarily in Caucasian women. However, to date, there is a dearth of data for Japanese postmenopausal women. In this study, we prospectively evaluated the effects of RLX on bone and lipid metabolism in fifty Japanese postmenopausal patients with untreated osteoporosis. We measured bone mineral density (BMD) by dual-energy X-ray absorptiometry at 7 sites including the lumbar spine, femoral neck, and distal radius. BMD was significantly increased at the lumbar spine both at 6 months and at 12 months compared with at baseline (p<0.01 for both), although the possibility could not be completely excluded that this increase may be partly explained by an apparent increase induced by degenerative changes in lumbar vertebrae since we had no control subjects to compare and be more certain of the findings in this study. Both bone-specific alkaline phosphatase (BAP) and serum N-terminal telopeptide of type I collagen (NTx) significantly decreased both at 6 months (p<0.01 for both) and at 12 months (p<0.01 for both) compared with at baseline, but not below the lower limit of the reference value. Total cholesterol and low-density lipoprotein cholesterol were significantly improved while triglycerides and high-density lipoprotein cholesterol were unaltered. Although longer and larger studies with fracture endpoints are needed to draw definite conclusions, our findings suggest the favorable effects of RLX on bone and lipid metabolism in Japanese postmenopausal women with osteoporosis as in Caucasian women.<br>

Journal

• Endocrine Journal

  Endocrine Journal 54 (6), 855-862, 2007

  The Japan Endocrine Society

Keywords

• Raloxifene
• Osteoporosis
• Bone mineral density
• Bone turnover
• Lipid

Details

• CRID: 1390282681275747968
• NII Article ID: 10021263533
• NII Article ID: 130004443335
• NII Book ID: AA10901436
• DOI: 10.1507/endocrj.k06-208
• ISSN: 13484540
• ISSN: 09188959
• Web Site: http://www.jstage.jst.go.jp/article/endocrj/54/6/54_K06-208/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2008213585
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed